OKYO OKYO Pharma

OKYO Pharma Limited ("OKYO" or the "Company") - Company Presentation

OKYO Pharma Limited ("OKYO" or the "Company") - Company Presentation

LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that, further to the announcement made on Friday 31 July, the investor webinar, hosted by RedChip Companies, on Sunday, August 2, 2020 can be viewed at .

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma LimitedWilly Simon+44 (0)20 7495 2379
Optiva Securities Limited



 		Robert Emmet+ 44 (0)20 3981 4173

For further information, please visit the Company's website at

EN
03/08/2020

Underlying

OKYOOKYO Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OKYO Pharma

 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerat...

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced it has received $1.9 million in non-dilutive funding to support its ongoing research and development programs. The funding wil...

July 17, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimo...

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visi...

July 16, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma to Present at the Bio International Convention

OKYO Pharma to Present at the Bio International Convention LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation during the Bio International Convention in Boston, MA. Dr. Jacob’s presentation will cover the development of urcosimod, OKYO’s lead clinical drug cand...

June 11, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob’s presentation will cover the development of...

May 19, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropa...

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP). Fast Track designation by the ...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch